Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals develops and commercializes oral small-molecule therapies for rare diseases, with a focus on the kallikrein-kinin system. Its FDA-approved product EKTERLY (sebetralstat) is an oral plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, and company updates often center on launch activity, product revenue, and use of oral on-demand therapy in HAE.
KalVista news also covers clinical and scientific updates for sebetralstat, including pediatric HAE work through the KONFIDENT-KID trial, medical-conference presentations, financial results, inducement equity grants, governance matters, capital-structure disclosures, and material agreements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.